Overview

Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to analyze whether Dabrafenib +/- Trametinib are effective in overall survival, response rates and toxicity in both programs.
Details
Lead Sponsor:
Grupo EspaƱol Multidisciplinar de Melanoma
Collaborator:
GlaxoSmithKline
Treatments:
Dabrafenib
Trametinib